Protection against Rift Valley fever virus infection in mice upon administration of interferon-inducing RNA transcripts from the FMDV genome
•Non-coding regions (NCRs) of the FMDV genome limited RVFV replication in mice.•Co-inoculation of IRES or 3′-NCR RNA transcripts with RVFV achieved full protection.•All transcripts induced the production of antiviral and pro-inflammatory cytokines. In this work we have addressed the effect of synthe...
Gespeichert in:
Veröffentlicht in: | Antiviral research 2014-09, Vol.109, p.64-67 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 67 |
---|---|
container_issue | |
container_start_page | 64 |
container_title | Antiviral research |
container_volume | 109 |
creator | Lorenzo, Gema Rodríguez-Pulido, Miguel López-Gil, Elena Sobrino, Francisco Borrego, Belén Sáiz, Margarita Brun, Alejandro |
description | •Non-coding regions (NCRs) of the FMDV genome limited RVFV replication in mice.•Co-inoculation of IRES or 3′-NCR RNA transcripts with RVFV achieved full protection.•All transcripts induced the production of antiviral and pro-inflammatory cytokines.
In this work we have addressed the effect of synthetic, non-infectious, RNA transcripts, mimicking structural domains of the non-coding regions (NCRs) of the foot-and-mouth disease virus (FMDV) genome on the infection of mice with Rift Valley fever virus (RVFV). Groups of 5 mice were inoculated intraperitoneally (i.p.) with 200μg of synthetic RNA resembling the 5′-terminal S region, the internal ribosome entry site (IRES) or the 3′-NCR of the FMDV genome. RNA inoculation was performed 24h before (−24h), 24h after (+24h) or simultaneously to the challenge with a lethal dose of RVFV. Administration of the IRES RNA afforded higher survival rates than administration of S or 3′NCR transcripts either at −24h or +24h after challenge. In contrast, when RNA inoculation and viral challenge were performed simultaneously, all mice survived in both IRES- and 3′NCR-inoculated groups, with an 80% survival in mice receiving the S RNA. Among survivors, a complete correlation between significant anti-RVFV circulating antibody titers and resistance to a second lethal challenge with the virus was observed, supporting a limited viral replication in the RNA-inoculated animals upon the first challenge. All three RNA transcripts were able to induce the production of systemic antiviral and pro-inflammatory cytokines. These data show that triggering of intracellular pathogen sensing pathways constitutes a promising approach towards development of novel RVF preventive or therapeutic strategies. |
doi_str_mv | 10.1016/j.antiviral.2014.06.010 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1627970888</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0166354214001727</els_id><sourcerecordid>1554473053</sourcerecordid><originalsourceid>FETCH-LOGICAL-c488t-139092d753e600850d99f3234c99a800d8663d6c1a55e7f5a340220b45dd33a73</originalsourceid><addsrcrecordid>eNqFkc2OFCEURitG47Sjr6BsTNxUCQUF1LIzOmoy_mSisyUMXFo6VdAC1cm8gw8tbbfjclYs7vm48J2meUVwRzDhb7edDsXvfdJT12PCOsw7TPCjZkWk6NsRj_xxs6okb-nA-rPmWc5bjDEXo3zanPVsFFRwsmp-f0uxgCk-BqQ32odc0LV3Bd3oaYI75GAPCdVFS0Y-uBPpA5q9AbTsDjE7--BzSfrvLLo6LpAcpBhaH-xifNig6y9rVJGQTfK7kpFLcUblJ6DLz-9u0AZCnOF588TpKcOL03ne_Lh8__3iY3v19cOni_VVa5iUpSW0_q-3YqDAMZYDtuPoaE-ZGUctMbaSc2q5IXoYQLhBU4b7Ht-ywVpKtaDnzZvjvbsUfy2Qi5p9NjBNOkBcsiK8F6PAUsqH0WFgTFA80IqKI2pSzDmBU7vkZ53uFMHqYE1t1b01dbCmMFfVWk2-PC1Zbmew97l_mirw-gTobPTkao_G5_-cFIzVUiq3PnJQ29t7SCobD8GA9amqUzb6Bx_zB_FJuuQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1554473053</pqid></control><display><type>article</type><title>Protection against Rift Valley fever virus infection in mice upon administration of interferon-inducing RNA transcripts from the FMDV genome</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Lorenzo, Gema ; Rodríguez-Pulido, Miguel ; López-Gil, Elena ; Sobrino, Francisco ; Borrego, Belén ; Sáiz, Margarita ; Brun, Alejandro</creator><creatorcontrib>Lorenzo, Gema ; Rodríguez-Pulido, Miguel ; López-Gil, Elena ; Sobrino, Francisco ; Borrego, Belén ; Sáiz, Margarita ; Brun, Alejandro</creatorcontrib><description>•Non-coding regions (NCRs) of the FMDV genome limited RVFV replication in mice.•Co-inoculation of IRES or 3′-NCR RNA transcripts with RVFV achieved full protection.•All transcripts induced the production of antiviral and pro-inflammatory cytokines.
In this work we have addressed the effect of synthetic, non-infectious, RNA transcripts, mimicking structural domains of the non-coding regions (NCRs) of the foot-and-mouth disease virus (FMDV) genome on the infection of mice with Rift Valley fever virus (RVFV). Groups of 5 mice were inoculated intraperitoneally (i.p.) with 200μg of synthetic RNA resembling the 5′-terminal S region, the internal ribosome entry site (IRES) or the 3′-NCR of the FMDV genome. RNA inoculation was performed 24h before (−24h), 24h after (+24h) or simultaneously to the challenge with a lethal dose of RVFV. Administration of the IRES RNA afforded higher survival rates than administration of S or 3′NCR transcripts either at −24h or +24h after challenge. In contrast, when RNA inoculation and viral challenge were performed simultaneously, all mice survived in both IRES- and 3′NCR-inoculated groups, with an 80% survival in mice receiving the S RNA. Among survivors, a complete correlation between significant anti-RVFV circulating antibody titers and resistance to a second lethal challenge with the virus was observed, supporting a limited viral replication in the RNA-inoculated animals upon the first challenge. All three RNA transcripts were able to induce the production of systemic antiviral and pro-inflammatory cytokines. These data show that triggering of intracellular pathogen sensing pathways constitutes a promising approach towards development of novel RVF preventive or therapeutic strategies.</description><identifier>ISSN: 0166-3542</identifier><identifier>EISSN: 1872-9096</identifier><identifier>DOI: 10.1016/j.antiviral.2014.06.010</identifier><identifier>PMID: 24973761</identifier><identifier>CODEN: ARSRDR</identifier><language>eng</language><publisher>Kidlington: Elsevier B.V</publisher><subject>Animal viral diseases ; Animals ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antibodies, Viral - immunology ; Antiviral agents ; Arboviroses ; Biological and medical sciences ; Cross Protection ; Foot and mouth disease virus ; Foot-and-Mouth Disease Virus - genetics ; Foot-and-Mouth Disease Virus - immunology ; Genome, Viral ; Human viral diseases ; Humans ; Infectious diseases ; Innate immunity ; Interferons - administration & dosage ; Medical sciences ; Mice ; Mice, Inbred BALB C ; Miscellaneous ; Non coding RNA regions ; Pharmacology. Drug treatments ; Rift Valley fever ; Rift Valley Fever - immunology ; Rift Valley Fever - prevention & control ; Rift Valley Fever - virology ; Rift Valley fever virus ; Rift Valley fever virus - immunology ; Rift Valley fever virus - physiology ; RNA, Viral - administration & dosage ; RNA, Viral - chemical synthesis ; RNA, Viral - genetics ; RNA, Viral - immunology ; Tropical viral diseases ; Vaccination ; Viral diseases ; Viral Vaccines - administration & dosage ; Viral Vaccines - chemical synthesis ; Viral Vaccines - genetics ; Viral Vaccines - immunology ; Virus Replication</subject><ispartof>Antiviral research, 2014-09, Vol.109, p.64-67</ispartof><rights>2014 Elsevier B.V.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2014 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c488t-139092d753e600850d99f3234c99a800d8663d6c1a55e7f5a340220b45dd33a73</citedby><cites>FETCH-LOGICAL-c488t-139092d753e600850d99f3234c99a800d8663d6c1a55e7f5a340220b45dd33a73</cites><orcidid>0000-0002-0801-9166 ; 0000-0002-7726-1343</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.antiviral.2014.06.010$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28744390$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24973761$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lorenzo, Gema</creatorcontrib><creatorcontrib>Rodríguez-Pulido, Miguel</creatorcontrib><creatorcontrib>López-Gil, Elena</creatorcontrib><creatorcontrib>Sobrino, Francisco</creatorcontrib><creatorcontrib>Borrego, Belén</creatorcontrib><creatorcontrib>Sáiz, Margarita</creatorcontrib><creatorcontrib>Brun, Alejandro</creatorcontrib><title>Protection against Rift Valley fever virus infection in mice upon administration of interferon-inducing RNA transcripts from the FMDV genome</title><title>Antiviral research</title><addtitle>Antiviral Res</addtitle><description>•Non-coding regions (NCRs) of the FMDV genome limited RVFV replication in mice.•Co-inoculation of IRES or 3′-NCR RNA transcripts with RVFV achieved full protection.•All transcripts induced the production of antiviral and pro-inflammatory cytokines.
In this work we have addressed the effect of synthetic, non-infectious, RNA transcripts, mimicking structural domains of the non-coding regions (NCRs) of the foot-and-mouth disease virus (FMDV) genome on the infection of mice with Rift Valley fever virus (RVFV). Groups of 5 mice were inoculated intraperitoneally (i.p.) with 200μg of synthetic RNA resembling the 5′-terminal S region, the internal ribosome entry site (IRES) or the 3′-NCR of the FMDV genome. RNA inoculation was performed 24h before (−24h), 24h after (+24h) or simultaneously to the challenge with a lethal dose of RVFV. Administration of the IRES RNA afforded higher survival rates than administration of S or 3′NCR transcripts either at −24h or +24h after challenge. In contrast, when RNA inoculation and viral challenge were performed simultaneously, all mice survived in both IRES- and 3′NCR-inoculated groups, with an 80% survival in mice receiving the S RNA. Among survivors, a complete correlation between significant anti-RVFV circulating antibody titers and resistance to a second lethal challenge with the virus was observed, supporting a limited viral replication in the RNA-inoculated animals upon the first challenge. All three RNA transcripts were able to induce the production of systemic antiviral and pro-inflammatory cytokines. These data show that triggering of intracellular pathogen sensing pathways constitutes a promising approach towards development of novel RVF preventive or therapeutic strategies.</description><subject>Animal viral diseases</subject><subject>Animals</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antibodies, Viral - immunology</subject><subject>Antiviral agents</subject><subject>Arboviroses</subject><subject>Biological and medical sciences</subject><subject>Cross Protection</subject><subject>Foot and mouth disease virus</subject><subject>Foot-and-Mouth Disease Virus - genetics</subject><subject>Foot-and-Mouth Disease Virus - immunology</subject><subject>Genome, Viral</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Innate immunity</subject><subject>Interferons - administration & dosage</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Miscellaneous</subject><subject>Non coding RNA regions</subject><subject>Pharmacology. Drug treatments</subject><subject>Rift Valley fever</subject><subject>Rift Valley Fever - immunology</subject><subject>Rift Valley Fever - prevention & control</subject><subject>Rift Valley Fever - virology</subject><subject>Rift Valley fever virus</subject><subject>Rift Valley fever virus - immunology</subject><subject>Rift Valley fever virus - physiology</subject><subject>RNA, Viral - administration & dosage</subject><subject>RNA, Viral - chemical synthesis</subject><subject>RNA, Viral - genetics</subject><subject>RNA, Viral - immunology</subject><subject>Tropical viral diseases</subject><subject>Vaccination</subject><subject>Viral diseases</subject><subject>Viral Vaccines - administration & dosage</subject><subject>Viral Vaccines - chemical synthesis</subject><subject>Viral Vaccines - genetics</subject><subject>Viral Vaccines - immunology</subject><subject>Virus Replication</subject><issn>0166-3542</issn><issn>1872-9096</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc2OFCEURitG47Sjr6BsTNxUCQUF1LIzOmoy_mSisyUMXFo6VdAC1cm8gw8tbbfjclYs7vm48J2meUVwRzDhb7edDsXvfdJT12PCOsw7TPCjZkWk6NsRj_xxs6okb-nA-rPmWc5bjDEXo3zanPVsFFRwsmp-f0uxgCk-BqQ32odc0LV3Bd3oaYI75GAPCdVFS0Y-uBPpA5q9AbTsDjE7--BzSfrvLLo6LpAcpBhaH-xifNig6y9rVJGQTfK7kpFLcUblJ6DLz-9u0AZCnOF588TpKcOL03ne_Lh8__3iY3v19cOni_VVa5iUpSW0_q-3YqDAMZYDtuPoaE-ZGUctMbaSc2q5IXoYQLhBU4b7Ht-ywVpKtaDnzZvjvbsUfy2Qi5p9NjBNOkBcsiK8F6PAUsqH0WFgTFA80IqKI2pSzDmBU7vkZ53uFMHqYE1t1b01dbCmMFfVWk2-PC1Zbmew97l_mirw-gTobPTkao_G5_-cFIzVUiq3PnJQ29t7SCobD8GA9amqUzb6Bx_zB_FJuuQ</recordid><startdate>20140901</startdate><enddate>20140901</enddate><creator>Lorenzo, Gema</creator><creator>Rodríguez-Pulido, Miguel</creator><creator>López-Gil, Elena</creator><creator>Sobrino, Francisco</creator><creator>Borrego, Belén</creator><creator>Sáiz, Margarita</creator><creator>Brun, Alejandro</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T7</scope><scope>7TM</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><orcidid>https://orcid.org/0000-0002-0801-9166</orcidid><orcidid>https://orcid.org/0000-0002-7726-1343</orcidid></search><sort><creationdate>20140901</creationdate><title>Protection against Rift Valley fever virus infection in mice upon administration of interferon-inducing RNA transcripts from the FMDV genome</title><author>Lorenzo, Gema ; Rodríguez-Pulido, Miguel ; López-Gil, Elena ; Sobrino, Francisco ; Borrego, Belén ; Sáiz, Margarita ; Brun, Alejandro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c488t-139092d753e600850d99f3234c99a800d8663d6c1a55e7f5a340220b45dd33a73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animal viral diseases</topic><topic>Animals</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antibodies, Viral - immunology</topic><topic>Antiviral agents</topic><topic>Arboviroses</topic><topic>Biological and medical sciences</topic><topic>Cross Protection</topic><topic>Foot and mouth disease virus</topic><topic>Foot-and-Mouth Disease Virus - genetics</topic><topic>Foot-and-Mouth Disease Virus - immunology</topic><topic>Genome, Viral</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Innate immunity</topic><topic>Interferons - administration & dosage</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Miscellaneous</topic><topic>Non coding RNA regions</topic><topic>Pharmacology. Drug treatments</topic><topic>Rift Valley fever</topic><topic>Rift Valley Fever - immunology</topic><topic>Rift Valley Fever - prevention & control</topic><topic>Rift Valley Fever - virology</topic><topic>Rift Valley fever virus</topic><topic>Rift Valley fever virus - immunology</topic><topic>Rift Valley fever virus - physiology</topic><topic>RNA, Viral - administration & dosage</topic><topic>RNA, Viral - chemical synthesis</topic><topic>RNA, Viral - genetics</topic><topic>RNA, Viral - immunology</topic><topic>Tropical viral diseases</topic><topic>Vaccination</topic><topic>Viral diseases</topic><topic>Viral Vaccines - administration & dosage</topic><topic>Viral Vaccines - chemical synthesis</topic><topic>Viral Vaccines - genetics</topic><topic>Viral Vaccines - immunology</topic><topic>Virus Replication</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lorenzo, Gema</creatorcontrib><creatorcontrib>Rodríguez-Pulido, Miguel</creatorcontrib><creatorcontrib>López-Gil, Elena</creatorcontrib><creatorcontrib>Sobrino, Francisco</creatorcontrib><creatorcontrib>Borrego, Belén</creatorcontrib><creatorcontrib>Sáiz, Margarita</creatorcontrib><creatorcontrib>Brun, Alejandro</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Antiviral research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lorenzo, Gema</au><au>Rodríguez-Pulido, Miguel</au><au>López-Gil, Elena</au><au>Sobrino, Francisco</au><au>Borrego, Belén</au><au>Sáiz, Margarita</au><au>Brun, Alejandro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Protection against Rift Valley fever virus infection in mice upon administration of interferon-inducing RNA transcripts from the FMDV genome</atitle><jtitle>Antiviral research</jtitle><addtitle>Antiviral Res</addtitle><date>2014-09-01</date><risdate>2014</risdate><volume>109</volume><spage>64</spage><epage>67</epage><pages>64-67</pages><issn>0166-3542</issn><eissn>1872-9096</eissn><coden>ARSRDR</coden><abstract>•Non-coding regions (NCRs) of the FMDV genome limited RVFV replication in mice.•Co-inoculation of IRES or 3′-NCR RNA transcripts with RVFV achieved full protection.•All transcripts induced the production of antiviral and pro-inflammatory cytokines.
In this work we have addressed the effect of synthetic, non-infectious, RNA transcripts, mimicking structural domains of the non-coding regions (NCRs) of the foot-and-mouth disease virus (FMDV) genome on the infection of mice with Rift Valley fever virus (RVFV). Groups of 5 mice were inoculated intraperitoneally (i.p.) with 200μg of synthetic RNA resembling the 5′-terminal S region, the internal ribosome entry site (IRES) or the 3′-NCR of the FMDV genome. RNA inoculation was performed 24h before (−24h), 24h after (+24h) or simultaneously to the challenge with a lethal dose of RVFV. Administration of the IRES RNA afforded higher survival rates than administration of S or 3′NCR transcripts either at −24h or +24h after challenge. In contrast, when RNA inoculation and viral challenge were performed simultaneously, all mice survived in both IRES- and 3′NCR-inoculated groups, with an 80% survival in mice receiving the S RNA. Among survivors, a complete correlation between significant anti-RVFV circulating antibody titers and resistance to a second lethal challenge with the virus was observed, supporting a limited viral replication in the RNA-inoculated animals upon the first challenge. All three RNA transcripts were able to induce the production of systemic antiviral and pro-inflammatory cytokines. These data show that triggering of intracellular pathogen sensing pathways constitutes a promising approach towards development of novel RVF preventive or therapeutic strategies.</abstract><cop>Kidlington</cop><pub>Elsevier B.V</pub><pmid>24973761</pmid><doi>10.1016/j.antiviral.2014.06.010</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-0801-9166</orcidid><orcidid>https://orcid.org/0000-0002-7726-1343</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0166-3542 |
ispartof | Antiviral research, 2014-09, Vol.109, p.64-67 |
issn | 0166-3542 1872-9096 |
language | eng |
recordid | cdi_proquest_miscellaneous_1627970888 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Animal viral diseases Animals Antibiotics. Antiinfectious agents. Antiparasitic agents Antibodies, Viral - immunology Antiviral agents Arboviroses Biological and medical sciences Cross Protection Foot and mouth disease virus Foot-and-Mouth Disease Virus - genetics Foot-and-Mouth Disease Virus - immunology Genome, Viral Human viral diseases Humans Infectious diseases Innate immunity Interferons - administration & dosage Medical sciences Mice Mice, Inbred BALB C Miscellaneous Non coding RNA regions Pharmacology. Drug treatments Rift Valley fever Rift Valley Fever - immunology Rift Valley Fever - prevention & control Rift Valley Fever - virology Rift Valley fever virus Rift Valley fever virus - immunology Rift Valley fever virus - physiology RNA, Viral - administration & dosage RNA, Viral - chemical synthesis RNA, Viral - genetics RNA, Viral - immunology Tropical viral diseases Vaccination Viral diseases Viral Vaccines - administration & dosage Viral Vaccines - chemical synthesis Viral Vaccines - genetics Viral Vaccines - immunology Virus Replication |
title | Protection against Rift Valley fever virus infection in mice upon administration of interferon-inducing RNA transcripts from the FMDV genome |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T08%3A48%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Protection%20against%20Rift%20Valley%20fever%20virus%20infection%20in%20mice%20upon%20administration%20of%20interferon-inducing%20RNA%20transcripts%20from%20the%20FMDV%20genome&rft.jtitle=Antiviral%20research&rft.au=Lorenzo,%20Gema&rft.date=2014-09-01&rft.volume=109&rft.spage=64&rft.epage=67&rft.pages=64-67&rft.issn=0166-3542&rft.eissn=1872-9096&rft.coden=ARSRDR&rft_id=info:doi/10.1016/j.antiviral.2014.06.010&rft_dat=%3Cproquest_cross%3E1554473053%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1554473053&rft_id=info:pmid/24973761&rft_els_id=S0166354214001727&rfr_iscdi=true |